NCT03262090

Brief Summary

Emergence agitation/delirium (EA/ED) is a common complication in pediatric surgery patients, which increases the risk of developing postoperative airway obstruction and respiratory depression. In infants, there is a high incidence of emergence agitation (EA) after desoflurane anesthesia. The aim of the present preliminary study was to determine the safety and efficacy of of intraoperative infusion of dexmedetomidine (DEX) that would prevent postoperative EA and ED in children undergoing day surgery with desoflurane anesthesia

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
389

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 18, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 25, 2017

Completed
24 days until next milestone

Study Start

First participant enrolled

September 18, 2017

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2019

Completed
6 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 21, 2019

Completed
Last Updated

June 25, 2019

Status Verified

June 1, 2019

Enrollment Period

1.7 years

First QC Date

August 18, 2017

Last Update Submit

June 24, 2019

Conditions

Keywords

Emergence Deliriumdesofluranegeneral anesthesia

Outcome Measures

Primary Outcomes (1)

  • incidence of emergence agitation at different time interval after emergence

    emergence agitation was evaluated by five-point scale

    at 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

Secondary Outcomes (3)

  • sedation scales at different time interval after emergence

    at 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

  • pain scale at different time interval after emergence

    at 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

  • incidence of emergence delirium at different time interval after emergence

    at 5min, 10min, 20min, 30min, 40min, 50min, 60min, 2h after emergence

Study Arms (6)

control group

NO INTERVENTION

Subjects were randomly assigned to receive saline before skin incision

0.2ug/kg dexmedetomidine

ACTIVE COMPARATOR

Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision

Drug: 0.2ug/kg dexmedetomidine

0.4ug/kg dexmedetomidine

ACTIVE COMPARATOR

Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision

Drug: 0.4ug/kg dexmedetomidine

0.6ug/kg dexmedetomidine

ACTIVE COMPARATOR

Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision

Drug: 0.6ug/kg dexmedetomidine

0.8ug/kg dexmedetomidine

ACTIVE COMPARATOR

Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision

Drug: 0.8ug/kg dexmedetomidine

1.0ug/kg dexmedetomidine

ACTIVE COMPARATOR

Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision

Drug: 1.0ug/kg dexmedetomidine

Interventions

subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision

Also known as: Age
0.2ug/kg dexmedetomidine

subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision

Also known as: Age
0.4ug/kg dexmedetomidine

subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision

Also known as: Age
0.6ug/kg dexmedetomidine

subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision

Also known as: Age
0.8ug/kg dexmedetomidine

subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision

Also known as: Age
1.0ug/kg dexmedetomidine

Eligibility Criteria

Age4 Months - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • patients who undergo elective unilateral inguinal hernia or hydrocele testis day surgery
  • Patients who are American Society of Anesthesiologists classification I and II
  • Patients who are 4 months through 15 years of age

You may not qualify if:

  • \. children with history of respiratory tract infection 1 week preoperatively. 2. patients with preoperative liver and/or kidney dysfunction, or with mental abnormalities.
  • \. patients with any congenital malformation or acquired disease that could increase the risks of anesthesia and the dose of anesthetics (such as, but not limited to, congenital heart disease, hydronephrosis, nutrition dysplasia). 4. patients with long-term use of sedative or analgesic drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangzhou Women and Children Medical Center

Guangzhou, Guangdong, 510000, China

Location

MeSH Terms

Conditions

Emergence Delirium

Interventions

DexmedetomidineAging

Condition Hierarchy (Ancestors)

DeliriumConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsGrowth and DevelopmentPhysiological Phenomena

Study Officials

  • Xia Zheng, Doctor

    Guangzhou Women and Children's Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: The aim of the present preliminary study was to determine the safety and efficacy of of intraoperative infusion of dexmedetomidine (DEX) that would prevent postoperative EA and ED in children undergoing day surgery with desoflurane anesthesia. Subjects who underwent day surgery were stratified into two age groups as follows: low to 3 years, and 3-9 years. Then they were randomly assigned to receive one of six doses of intravenous dexmedetomidine: 0,0.2, 0.4, 0.6, 0.8 ,1.0ug/kg before skin incision.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

August 18, 2017

First Posted

August 25, 2017

Study Start

September 18, 2017

Primary Completion

May 15, 2019

Study Completion

May 21, 2019

Last Updated

June 25, 2019

Record last verified: 2019-06

Locations